Acquisition Completed

BioCryst Pharmaceuticals acquisition of Astria Therapeutics

US$700m enterprise value

Announced 14 Oct 2025

Advisers

Astria Therapeutics

Target

Financial adviser
Legal adviser

BioCryst Pharmaceuticals

Acquirer

Financial adviser
Legal adviser
Target
Astria Therapeutics
Acquirer
BioCryst Pharmaceuticals
Target based in
United States
Buyer based in
United States
Completed
23 Jan 2026
Sector
Biotech
Tags
Biotech, Rare Disease, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.